Anthocyanin-rich Blackcurrant and Vascular Function
Not Applicable
Completed
- Conditions
- InflammationVascular Stiffness
- Registration Number
- NCT02459756
- Lead Sponsor
- University of Reading
- Brief Summary
Regular consumption of fruits and vegetables may improve human health and reduce the risk of chronic diseases, such as heart disease, certain cancers and type 2 diabetes, but the active components and the underlying mechanisms are poorly understood. Berry fruits are abundant in anthocyanins and this study aims to test the hypothesis that ingestion of an anthocyanin-rich blackcurrant beverage will improve markers of cardiovascular health (health of blood vessels, inflammation and platelet function). Further, the study will investigate the anthocyanin bioavailability from the blackcurrant beverage.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 23
Inclusion Criteria
- Aged 30-55 years
- Non-smoker
- BMI between 20 - 30 kg/m2
- Generally healthy as established by a 'health and lifestyle' questionnaire and a screening blood sample
- Blood pressure < 140/90mmHg
- Total cholesterol < 6.2 mmol/L
- Fasting glucose < 7.0 mmol/L
Exclusion Criteria
- Diabetes mellitus
- Heart problems, stroke, vascular disease
- Inflammatory disease
- Kidney, liver, pancreas or gastrointestinal diseases
- Medication for hyperlipidaemia, hypertension, hypercoagulation, inflammatory conditions
- Asthma
- Allergies
- Smokers (social smokers who agree to abstain for 1 month before and during the study not excluded)
- Taking phytochemical, antioxidant or fish oil supplements (unless willing to stop for the study period)
- Taking aspirin > 2 times per month and unwilling to abstain from aspirin ingestion for 14 days prior each study visit
- History of alcohol misuse
- Consumption of alcohol >21 units (men) or >15 units (women)
- Vegans
- Intense aerobic exercise >20 min 3 x per week
- Participation in another clinical trial
- Antibiotics in previous 3 months before study
- Low haemoglobin levels
- Females who are pregnant, lactating, or if of reproductive age and not using a reliable form of contraception (including abstinence)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method Change from baseline in platelet function measured by agonist-induced platelet aggregation Acute study: measured at baseline and 2 and 4 h post intervention Change from baseline in vascular reactivity measured by flow-mediated dilatation (FMD) Acute study: measured at baseline and 1, 2, 4 and 6 h post intervention
- Secondary Outcome Measures
Name Time Method Change from baseline in the concentration of polyphenols and their metabolites and degradants in blood and urine samples measured by HPLC-MS/MS Acute study: plasma measured at baseline and 1, 2, 4, 6 and 24 h post intervention, urine measured at baseline and 1, 2, 4, 6 and 6-24 h post intervention Change from baseline in vascular function measured by digital volume pulse (DVP) Acute study: measured at baseline and 2, 4 and 6 h post intervention Change from baseline in blood pressure Acute study: measured at baseline and 1, 2, 4 and 6 h post intervention Change from baseline in the concentration of nitric oxide in plasma measured by ozone-based chemiluminescence Acute study: measured at baseline and 1, 2, 4 and 6 h post intervention Change from baseline in the concentration of selected cytokines (TNF-a, IL-1b, IL-6, IL-8 and IL-10) in plasma measured using a cytometric bead array kit from BD Biosciences Acute study: measured at baseline and 1, 2, 4 and 6 h post intervention Change from baseline in platelet function (numbers of circulating micro particles by nano particle tracking analysis) Acute study: measured at baseline and 1, 2, 4 and 6 h post intervention (urine metabonomics additionally 6-24h) Metabonomics on urine and plasma samples measured by nuclear magnetic resonance spectroscopy Acute study: measured at baseline and 1, 2, 4 and 6 h post intervention (urine metabonomics additionally 6-24h)
Trial Locations
- Locations (1)
University of Reading
🇬🇧Reading, United Kingdom